甲状腺眼病临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 甲状腺眼病（国际通用名 thyroid eye disease）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖突眼等说法。

正在招募的甲状腺眼病新药试验

• A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

  III 期招募中中国NCT07113262

• Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy

  不适用招募中中国NCT07381413

• The Myelin Disorders Biorepository Project

  不适用招募中美国NCT03047369

• A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease

  IV 期招募中中国NCT07265258

• Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

  III 期招募中美国NCT07753603

• A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

  IV 期招募中中国NCT06927375

• Preoperative Corticosteroids in Autoimmune Thyroid Disease

  IV 期招募中美国NCT05435547

• Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

  II 期招募中美国澳大利亚NCT07682896

• NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

  I 期招募中美国西班牙NCT07305818

• Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

  不适用招募中中国NCT07301892

• Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

  III 期招募中ThailandNCT06392906

• Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease

  早期 I 期招募中中国NCT07129642